Accord BioPharma Inc.’s Stelara biosimilar is now available in prefilled syringes.
Ustekinumab-srlf (Imuldosa) prefilled syringes are priced at the lowest wholesaler acquisition cost (WAC) among all branded ustekinumab biosimilars at a 92% discount from Stelara (Janssen Biotech, Inc.). The vial formulation offers a 33% discount.
Accord BioPharma is launching Imuldosa with a $0 co-pay program for eligible patients with plaque psoriasis, psoriatic arthritis, and Crohn’s disease and ulcerative colitis.
The biosimilar is approved to treat:
- adults and children aged 6 years and up with moderate-to-severe psoriasis who may benefit from taking injections or pills or phototherapy
- adults and children aged 6 and up with active psoriatic arthritis
- adults with moderately to severely active Crohn’s disease
- adults with moderately to severely active ulcerative colitis
